NCT01166139View on ClinicalTrials.gov

Nilotinib in the Treatment of Systemic Sclerosis

PHASE2CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

July 31, 2014

Study Completion Date

January 31, 2015

Conditions

Systemic Sclerosis

Interventions

DRUG

Nilotinib (Tasigna)

Patients will be treated with Nilotinib 400 mg two times a day for 6 months.

Trial Locations (1)

10021

Hospital for Special Surgery, New York

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Rudolph Rupert Scleroderma Program

UNKNOWN

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Hospital for Special Surgery, New York

OTHER